지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 74 - 79 (6page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been used to treat chronic hepatitis C without severe adverse effects and have achieved a sustained viral response (SVR) rate of 80-90% with short treatment duration. We were interested to determine whether all patients who failed to respond to or were ineligible for interferon-based therapy could be treated with DAAs.
Methods: Medical records of patients with positive serum anti-hepatitis C virus (HCV) or HCV RNA between January 2009 and December 2013 were reviewed. Demographic, clinical, and treatment data were collected for analysis.
Results: A total of 876 patients were positive for both anti-HCV and HCV RNA. Of these, 244 patients were eligible for interferon, although this was associated with relapse in 39 (16%) of patients. In total, 130 patients stopped interferon therapy (67% adverse effects, 28% non-adherent, 4% malignancy, 1% alcohol abuse) and 502 patients were ineligible (66% medical contraindications, 25% non-adherent, 5% socioeconomic problems). Among 671 patients who were ineligible for or failed to respond to interferon therapy, more than 186 (27.7%) could not be treated with DAA due to financial, social, or cancer-related conditions.
Conclusions: Newly developed DAAs are a promising treatment for patients with chronic hepatitis C who are ineligible for or failed to respond to interferon-based therapy. Nevertheless, not all chronic hepatitis C patients can be treated with DAAs due to various reasons.
목차
등록된 정보가 없습니다.
참고문헌 (17)
참고문헌 신청
Conti F / 2016 / Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals / J Hepatol 65 : 727 ~ 733
Cox AL / 2015 / MEDICINE. Global control of hepatitis C virus / Science 349 : 790 ~ 791
European Association for Study of Liver / 2015 / EASL recommendations on treatment of hepatitis C 2015 / J Hepatol 63 : 199 ~ 236
Falck-Ytter Y / 2002 / Surprisingly small effect of antiviral treatment in patients with hepatitis C / Ann Intern Med 136 : 288 ~ 292
Fried MW / 2002 / Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / N Engl J Med 347 : 975 ~ 982
Cox AL / 2015 / MEDICINE. Global control of hepatitis C virus / Science 349 : 790 ~ 791
European Association for Study of Liver / 2015 / EASL recommendations on treatment of hepatitis C 2015 / J Hepatol 63 : 199 ~ 236
Falck-Ytter Y / 2002 / Surprisingly small effect of antiviral treatment in patients with hepatitis C / Ann Intern Med 136 : 288 ~ 292
Fried MW / 2002 / Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / N Engl J Med 347 : 975 ~ 982
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data
Gut and Liver
2017 .01
-
Hepatitis C Virus and Antiviral Drug Resistance
Gut and Liver
2016 .01
-
Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
Gut and Liver
2017 .07
-
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Clinical and Molecular Hepatology
2020 .01
-
Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Treatment Outcomes of HCV Infection in People Living with HIV: A Case Series from a Single Center in Korea
Infection and Chemotherapy
2024 .09
-
Chronic Hepatitis C Virus Infection, Why Not Treat Now?
대한류마티스학회지
2018 .01
-
Current and future strategies for the treatment of chronic hepatitis C
Clinical and Molecular Hepatology
2021 .01
-
Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study
Gut and Liver
2020 .01
-
Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
Clinical and Molecular Hepatology
2018 .01
-
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Journal of Korean Medical Science
2019 .01
-
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Gut and Liver
2017 .01
-
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
Clinical and Molecular Hepatology
2018 .01
-
Genotypes of Hepatitis C Virus in Relapsed and Non-respondent Patients and their Response to Anti-Viral Therapy in District Mardan, Khyber Pakhtunkhawa, Pakistan
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Hepatitis C Viral Infection in Children: Updated Review
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
Gut and Liver
2019 .01
-
Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling
Clinical and Molecular Hepatology
2018 .01
-
Is the Prevalence of Chronic Hepatitis B Really Increasing in Korea?
Journal of Korean Medical Science
2024 .01
-
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives
Gut and Liver
2017 .01
-
Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
Gut and Liver
2017 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0